Metra/Ciba
This article was originally published in The Gray Sheet
Executive Summary
Ciba Corning Diagnostics gains rights to use Metra Biosystems' pyridinium crosslinks technology to develop a diagnostic test for bone resorption for its fully automated ACS: 180(R) system. CCD will commercialize the test internationally except in Japan, and will pay "upfront licensing fees and ongoing royalties," Metra says. In December, the Palo Alto, California-based firm negotiated a deal under which Lilly subsidiary Hybritech will develop a pyridinium crosslinks-based laboratory test. Metra's Pyrilinks bone resorption test is "under review at FDA"